SCHEMBL24258331

SCHEMBL24258331

BCc1ccc(CCl)cc1

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11961978 0.83 ESR1 (0.32)
SCHEMBL97582 0.83 CA1 (0.52) CA1CA2
SCHEMBL12028140 0.75
SCHEMBL12451910 0.75
SCHEMBL187751 0.73 HRH3 (0.47) CA1CA2
SCHEMBL5885169 0.73 CYP3A4 (0.47) CA1CA2
SCHEMBL9456876 0.73 HRH3 (0.47) CA1CA2
SCHEMBL13658160 0.73 GFER (0.47) CA1CA2
SCHEMBL11323181 0.73 CYP3A4 (0.47) CA1CA2
Water SCHEMBL27740233 0.73 CA1 (0.41) CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177612-B1 OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES NUEVOLUTION AS (DK) 2022-02-23 EP disclosed